Systematic Review Article | Iran J Med Microbiol. 2025; 19(5): 291-306

Category: Antibiotic Resistance | Peer Reviewed | Open Access

10.30699/ijmm.19.5.291

Iranian Journal of Medical Microbiology | ISSN:2345-4342

Environmental Drivers of Antimicrobial Resistance and Strategies for Mitigation

Sharmila Jayasena*, Meran Keshawa Ediriweera, Chaniru Udukumbura

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

ABSTRACT

The spread of antibiotic resistance among pathogenic bacteria has reached a critical point, with the emergence of resistant strains for the last line antibiotics, alongside a dwindling discovery pipeline for novel antimicrobials. This review aimed to highlight the dual role of the environment in the development of antimicrobial resistance as well as the source for the discovery of novel antimicrobials. Microorganisms live in heterogeneous communities and competition for the survival applies evolutionary pressure to both antimicrobial metabolites production and tolerance development. Exposure to environmental chemicals, either naturally occurring or due to anthropogenic activities, also leads to the development of tolerance mechanisms. Further, antimicrobial resistance genes, which attain mobility during evolution, may be transferred to other species through horizontal gene transfer. While overuse and misuse of antibiotics is identified as a key agent for antimicrobial resistance, we should take in consideration that resistance mechanisms were present in the environment long before their discovery. The biosynthetic capacity of microorganisms for secondary metabolites far exceeds what has been characterized so far. Similarly, mechanisms for tolerance and resistance for these natural antibiotics may still be awaiting discovery. Future challenges lie in the discovery of novel antibiotic classes for which tolerance mechanisms have not yet been transferred to clinical strains. Novel strategies, guided by genomics and computational methods, will accelerate antibiotic discovery.

Keywords: Antimicrobial Resistance, Drug Resistance, Environmental Microbiology Horizontal Gene Transfer; Secondary Metabolite, Tolerance Mechanism

Received: 2025/06/12; **Accepted**: 2025/10/04; **Published Online:** 2025/11/11;

Corresponding Information: **Sharmila Jayasena**, *Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka* & Email: sharmila@bmb.cmb.ac.lk

Use a device to scan and read the article online

Jayasena S, Ediriweera M K, Udukumbura C. Environmental Drivers of Antimicrobial Resistance and Strategies for Mitigation. Iran J Med Microbiol. 2025;19(5):291-306.

Download citation: BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks

Send citation to: Mendeley Zotero RefWorks

Graphical Abstract



(Prepared by Authors, 2025)

1. Introduction

The appearance of pathogenic microorganisms, particularly bacteria, displaying antimicrobial resistance (AMR) has reached an alarming rise in recent years. It has been predicted that by 2050, AMR would be responsible for 10 million deaths per year (1). Consequently, the World Health Organization (WHO) has categorized AMR as a global threat (2).

The AMR issue is multifaceted caused by: the spread of resistant pathogenic strains demonstrated by their emergence in new environments inhabited by humans, particularly hospitals, the appearance of new pathogenic species that have acquired resistance to existing antibiotics through the acquisition of resistance genes, and the emergence of new strains resistant to the 'last line' antibiotics.

The ESKAPE pathogens (*Enterococcus (E.) faecium, Staphylococcus (S.) aureus, Klebsiella (K.) pneumoniae, Acinetobacter (A.) baumannii, Pseudomonas (P.) aeruginosa and Enterobacter (E.)* spp) continue to challenge healthcare therapeutic intervention despite introduction of new antibiotics (3). Extensive-Drug-Resistant tuberculosis (XDR-TB) is now considered a global pandemic with low detection rates contributing to mortality (4). Furthermore, new resistant isolates continue to be reported across the globe. For example, tigecycline-resistant *Escherichia (E.) coli* isolates that exert resistance through a mobile resistance mechanism (plasmid mediated) has been reported from China (5). In 2024, a novel strain of XDR *Shigella sonnei* was reported in California (6). An emerging highly resistant clone (ST164) of Carbapenam-resistant *Acinetobactoer baumannii* was identified through a longitudinal genomics study in an ICU in Hangzhou China in 2024 (7). These examples represent just a few of the reports that highlight the increasing threat of AMR.

In addition to bacteria, the spread of multi-drug resistant (MDR) *Plasmodium falciparum* challenges the malaria control and elimination efforts in affected countries. The resistance mechanisms; chloroquine resistance transporter (Pfcrt) and multidrug-resistant gene 1 (Pfmdr-1) are well established (8).

Furthermore, clinically relevant antiviral resistance is also observed for some viral pathogens such as human immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis B virus (HBV) and SARS-CoV-2. Due to high mutation rates of viruses, particularly RNA viruses, the development of antiviral therapies may often be outpaced by the appearance of viral variants, where often a single base substitution in their genome may be sufficient to confer resistance (9).

Although AMR cumulatively refers to the resistance of bacteria, fungi, viruses, and parasites by definition, a significant portion of the global burden of AMR is borne by antibiotic resistant bacteria **(10)**. As such, this review predominantly focused on antibiotic resistance issue.

All these aspects of AMR have negatively impacted the treatment options particularly for bacterial infections **(10)**, and they are predicted to result in a significant mortality burden in the next few decades **(1)**. Therefore, there is an urgent need to control the spread of AMR while simultaneously seeking novel antimicrobials to combat infections.

The implementation of programs to combat AMR in low-income countries may be adversely affected by prioritization of programs to combat other issues amidst ongoing economic struggles **(11)**. However, an alarming increasing trend of antibiotic resistance has been observed in several South-East Asian countries, despite WHO initiatives advocating for antimicrobial stewardship **(12)**. AMR itself further imposes significant economic losses, particularly in the eleven countries of the WHO South-East Asian region. A recent study conducted in Sri Lanka reported the highest resistance among human samples towards beta (β)-lactam antibiotics, while among poultry and aquaculture samples, the highest resistance was found to be towards erythromycin **(11)**. Furthermore, while much of the emphasis has been focused on the use of antibiotics in the medical sector, their use in crop management is likely another significant environmental driver in the spread of AMR, particularly in the low-and middle-income countries **(13)**.

The overuse and misuse of antibiotics is considered a primary cause of the spread of resistance and their regulated use is considered as the path to control resistance issue. This review aims to emphasize the critical role of the environment in the evolution and spread of antimicrobial resistance. More importantly, it highlights the need to consider the mechanisms of microbial responses to environmental chemicals, particularly in terms of how resistance is induced, with the aim of guiding future research in the discovery of new antimicrobials.

2. The Environment as a Reservoir for AMR

The groundbreaking discovery and experimental determination of the antibacterial activity of 'penicillin' secreted by the mold *Penicillium*, which contaminated a petri dish of *Staphylococcus* **(14)**, and the subsequent isolation and chemical characterization of penicillin led to a paradigm shift in the treatment of infections in the 1940s. The two decades which followed (1940s-1960s), were in essence, the 'age of discoveries' for antimicrobial natural products, with the isolation of numerous antibiotic-producing bacteria from the environment, particularly soil **(14)**.

The environment plays a crucial role in the evolution of AMR by acting as a reservoir for resistant bacteria and resistance genes, and enabling their dissemination through water, soil, and air, where they can persevere and possibly encounter humans, animals, and plants. In addition, the environment can also enable the selection and maintenance of resistant bacteria through several mechanisms. Survival pressures or external influences in the environment, temperature fluctuations, exposure to natural antibiotics, and competition with other microorganisms, can drive the evolution of resistant bacteria **(10)**.

Antimicrobials (eg: antibiotics, antivirals, antifungals, and antiparasitic drugs) as well as heavy metals and biocides (biosurfactants & disinfectants) are key environmental drivers of AMR. Antibiotics and the microorganisms secreting them were present in the environment long before being discovered and exploited by humans. This is evidenced by the isolation of bacteria from pristine environments with the capacity to produce antibiotics as well as carrying antibiotic resistance genes (ARGs) **(15)**.

Multiple ARGs associated with different antibiotic classes were discovered in ancient viable bacteria (*Staphylococcus hominis*) isolated from permafrost (soil that remain at -10 to -5°C for at least two years) in the River Lena region in Russia, estimated to be up to 3.5 million years old **(16)**. More recently, Nawas *et al* **(17)** reported the presence of multiple ARGs among 65 culturable Gram-positive and Gram-negative bacteria isolated from the Karakorum Mountain range in Pakistan. Reports of various bacterial genera with the capacity to secrete antimicrobials isolated from the Antarctica have been reviewed by Núñez-Montero and Barriento **(18)**.

Antibiotics are essentially microbial weaponry, enabling them to both overcome their competitors and protect themselves from surrounding threats. The ability to secrete an antibiotic gives an organism an edge over the others, enabling them to colonize and potentially dominate a particular environmental niche **(19)**. In response, bacteria habituating these environments would evolve mechanisms to resist and tolerate these chemical attacks.

Another factor to bear in mind is that much of the research on AMR has been on organisms encountered in human infections and animal husbandry and the

antibiotics currently developed for societal use. This also includes the investigations carried out into ancient bacteria. A significantly larger fraction of microorganisms that produce antimicrobials and harbor resistance genes are present in the environment **(20)**. Most importantly, one can postulate that there will be novel antibiotic classes and resistance mechanisms among them yet undiscovered. Table 1 provides a comprehensive overview of various antibiotic classes developed for the clinical use, including their origins, mechanisms of action, and resistance mechanisms. The chemical structures of key antibiotics of different classes, highlighting their structural diversity and variation in size are shown in Figure 1.

Table 1. Morphological characteristics of the isolated bacterial strains.

Classes of antibiotics	Example/s	Discovery period	Organism/ origin	Mechanism of action (Target)	Common resistance mechanism	References
	Antibiotics from Actinomycetes					
Aminoglycosides	Streptomycin	1944	*Streptomyces griseus*	Inhibits protein synthesis (30S ribosomal subunit)	Enzymatic inactivation (ribosome methyltransferases)	**(21, 22)**
Amphenicols	Chloramphenicol	1947	*Streptomyces venezuelae*	Inhibits protein synthesis (50S ribosomal subunit)	Enzymatic inactivation (chloramphenicol acetyltransferases)	**(23, 24)**
Tetracyclines	Tetracycline	1948	*Streptomyces aureofaciens*	Inhibits protein synthesis (30S ribosomal subunit)	Target modification and efflux pumps	**(25)**
Tuberactinomycins	Viomycin (a peptide antibiotic)	1951	*Streptomyces puniceus*	Inhibits protein synthesis: mRNA translocation (Inter-subunit bridge of 30S and 50S ribosomal subunits)	Target modification	**(26, 27)**
Macrolides	Erythromycin azithromycin	1952	*Saccharopolyspora erythraea*	Inhibits protein synthesis (50S ribosomal subunit)	Target modification and efflux pumps	**(28, 29)**
Streptogramins*	Pristinamycin	1953	*Streptomyces pristinaespiralis*	Inhibits protein synthesis-elongation (50S ribosomal subunit)	Target modification, antibiotic inactivation and efflux pumps	**(30)**
Glycopeptides	Vancomycin	1955	*Amycolatopsis orientalis*	Inhibits cell wall synthesis (PG precursor lipid II)	Target modification	**(31, 32)**
Cycloserines	Seromycin	1955	*Streptomyces orchdaceus*	Inhibits cell wall synthesis (inhibits alanine racemase (Alr) and D-lla:D-ala ligase (Ddl))	Target modification (low mutation rate)	**(33, 34)**
Lincosamides	Lincomycine (Clindamycin) *	1962	*Streptomyces lincolnensis*	Inhibits protein synthesis (50S ribosomal subunit)	Target modification: ribosome methylation	**(29, 35)**
Ansamycins	Rifampicin	1965	*Amycolatopsis rifamycinica*	Inhibits RNA synthesis	Target modification by mutation (rpoB gene)	**(36, 37)**

Classes of antibiotics	Example/s	Discovery period	Organism/ origin	Mechanism of action (Target)	Common resistance mechanism	References
Phosphonates	Fosfomycin	1969	*Streptomyces fradiae*	Inhibits cell wall synthesis MurA (UDP-GlcNAc- 3-enolpyruvyltransferase)	Mutational target modification (murA), enzymatic inactivatio	(38)
Carbapenems (β- lactam antibiotics)	thienamycin	1976	*Streptomyces cattleya*	Inhibits cell wall synthesis	Enzymatic inhibition	(39)
Lipopeptides	Daptomycin,	1987	*Streptomyces roseosporus*	Gram-positive cell membranes undergo depolarization and permeabilization.	Target modification, antibiotic inactivation and efflux.	(40)
Antibiotics from other bacteria						
Mupirocin	Mupirocin	1971	*P. fluorescens*	Inhibits protein synthesis (isoleucyl t-RNA synthetase)		(41)
Monobactams (β-lactam antibiotics)	Aztreonam (synthetic)	1981	*Chromobacterium violaceum*	Inhibits cell wall synthesis: penicillin-binding proteins	Enzymatic inhibition of antibiotic (β lactamase)	(42)
Polypeptides	Gramicidin A	1940s	*Bacillus brevis*	Increase cell membrane permeation (formation of ion channels); hydroxyl radical formation		(43)
	Bacitracin (topical use)	1945	*Bacillus subtilis* group	Inhibits cell wall synthesis	Efflux pumps	(44)
Polymixins* (lipopeptide)	Polymyxin E (colistin)		*Paenibacillus polymyxa*	Cell wall: outer membrane disruption	Target modification	(45)
Antibiotics of fungal origin						
Penicillins (β-lactams)	Penicillin, amoxicillin* and flucloxacillin*	1929	*Penicillium notatum, P. chrysogenum*	Inhibits cell wall (peptidoglycan) synthesis:	Enzymatic inhibition (β lactamase)	(14, 46)
Cephalosporins (β-lactams)	Cephalexin	1948	*Cephalosporium acremonium*	Inhibits cell wall synthesis: penicillin-binding proteins	Enzymatic inhibition (β lactamase)	(46)
Pleuromutilins	Pleuromutilin Retapamulin*	1950s	*Pleurotus mutilus (Clitophilus scyphoides)*	Inhibits protein synthesis (50S ribosomal subunit - peptidyl transferase center)	Target modification (resistance is low)	(47)
Fusidic acid	Fusidic acid	1958	*Fusidium coccineum*	Inhibits protein synthesis (elongation factor G)	Target protection	(48)

***: show semisynthetic derivatives**



Figure 1. The chemical structures of key antibiotics of different classes. It highlights their structural diversity and variation in size **(Prepared by Authors, 2025)**

3. Microbial Strategies for Antibiotic Resistance

In the environment, microbial cell walls provide a physical barrier protecting them from a variety of chemical threats. The cell envelope of Gram-negative bacteria provides a more effective barrier for the entry of toxins, compared to that of Gram-positive bacteria **(20, 49)**. Fungal cell walls carry a layer of protective chitin over the cell membrane. Thus, a chemical that can modify the cell wall or interfere with the synthesis of its components will be an effective antimicrobial agent **(50)**. In fact, several antibiotics such as vancomycin and carbapenems in clinical use target microbial cell wall (Table 1).

Furthermore, most microbes when growing naturally live in often heterologous communities, forming biofilms. The biofilm, which comprises a self-secreted and dynamic extracellular matrix in which the microbes are embedded, provides an additional layer of physical protection. The role of biofilms in promoting antibiotic resistance and tolerance has been recently reviewed **(51)**. Cells in a biofilm may be up to ~1000 fold more tolerant to antimicrobial agents than their planktonic counterparts, which may be in part associated with horizontal gene transfer (HGT) **(51)**.

The cell membranes also provide a permeability barrier for the passage of molecules in an out of the cell. The composition of the outer membrane lipids as well as the

expression or function of porins determines the accessibility of hydrophilic antibiotics with intracellular targets **(52)**.

Additionally, microbes possess and utilize multiple complementary molecular mechanisms to resist the effects of environmental chemical onslaughts such as membrane efflux systems, enzymatic inactivation of antibiotics, and target modification. Resistance is often brought by combination of multiple modes of action.

All bacteria possess multiple efflux systems that serve to remove toxins from the cell, thereby preventing the accumulation of toxins to the adequate levels and binding to their cellular targets. Some efflux systems may be specific for a particular antibiotic whereby they may be activated only in the presence of that antibiotic, while others may be non-selective, thus providing general protection. Bacterial efflux systems and the effect of inhibitors on resistance have been recently reviewed **(53)**. In a recent study, antibiotic–induced overexpression of 10 selected efflux pump genes was investigated in a mixture of drug resistant and sensitive *Mycobacterium (M.) tuberculosis* clinical isolates. The study suggests that rifampicin resistance was strongly linked to overexpression of efflux pumps **(54)**. Their investigations further supported the concept that microbes most likely use multiple mechanisms of resistance in response to antibiotics and other toxins.

Enzymatic inactivation of antibiotics is a key mechanism used by bacteria to counter the effects of antibiotics. Organisms such as *Pseudomonas* produce β lactamases, which break the amide bond of the β-lactam ring of antibiotics. Aminoglycoside-inactivating enzymes such as aminoglycoside phosphotransferases, acetyltransferases and aminonucleotidyltransferases have also been described in *Pseudomonas* cases **(55)**.

Structural alterations of antibiotic targets are major resistance mechanisms observed among bacteria. Modification of the target could be expected to arise as a self-resistance mechanism, by the antibiotic producer. It may also originate as a mutagenic alteration that is maintained through evolution based on fitness cost. The alteration in antibiotic targets has been mostly observed in *P. aeruginosa* among others **(55)**.

It can be rationalized that microorganisms that secrete antimicrobials have to ensure a mechanism to safeguard them, particularly if the antibiotic is produced in its active form. As such, self-resistance mechanisms would be expected to evolve along with the ability to produce an antimicrobial compound. In fact, these self-resistance mechanisms may account for the origin of at least some antimicrobial resistance **(55, 56)**.

The discovery of ARGs in bacteria isolated from the natural environments with little or no anthropogenic interference supports the concept that antibiotic resistance originated naturally from the environment, prior to the anthropogenic use of antibiotics **(55, 56)**. Genes providing resistance to rifampicin, amino coumarine, and glycopeptides were discovered in isolates from arctic permafrost while ARGs for macrolides and glycopeptides have been discovered in deep sea sediments in the gulf of Khanbhat and the Arabian Sea **(57, 58)**.

4. Role of Environmental Chemical Toxins in Driving AMR

The environment receives chemicals from various sources, including industrial activities, waste disposals, livestock farming, agriculture, some domestic activities, and consumer products. These chemicals can pass through water, air, and soil and accumulate in the environment, leading to the development of AMR. Common environmental chemical toxins such as heavy metals (cadmium, lead, and mercury), metals (zinc and silver), nanoparticle forms of metals, pesticides, disinfectants, as well as several pharmaceuticals including antibiotics, antifungal agents, and chemotherapeutics have been linked to AMR **(10, 15)**.

Silver has a long history in the treatment of bacterial infections before the invention of antibiotics. In comparison with other forms of silver, due to their smaller particle size, silver nanoparticles (AgNPs) exert promising broad-spectrum antibacterial effects by disrupting the architecture of bacterial cells and altering bacterial cell metabolism **(59)**. In addition to their antibacterial effects, AgNPs have shown wound healing properties and are used as anticancer drugs and drug delivery vehicles **(60)**. An estimated annual production of approximately 200 - 500 tons of AgNPs, suggests an extensive presence in various environments **(61, 62)**. Concentrations ranged from nanograms per liter (ng/L) to milligrams per liter (mg/L) are found in the environment, highlighting AgNPs as a growing environmental contaminant. AgNPs and Ag+ at environmentally relevant concentrations were found to promote the conjugative gene transfer of plasmid-borne ARGs through generation of reactive oxygen species (ROS) and increasing cell membrane permeability **(59)**.

Nano-titanium dioxide (nano-TiO2) is used to break down contaminants in air and water treatment processes. It is also used as a coloring agent in the cosmetic and food industry, paint and plastic production, as well as hydrogen production and the solar cell industry. This has raised concerns about the potential environmental accumulation of nano-TiO2 in large quantities. Due to its antimicrobial effects, nano-TiO2 is used to coat medical devices like implants and catheters to prevent infections **(63)**. Exposure to nano-TiO2 was also shown to prompt horizontal transfer of ARGs mediated by RP4 plasmid between *E. coli* strains,

highlighting the potential role of nano-TiO2 in the development of AMR **(64)**.

Heavy metals, namely Cu(II), Ag(I), Cr(VI), and Zn(II), at environmentally relevant and sub-inhibitory concentrations, were found to trigger the conjugative transfer of ARGs between *E. coli* strains through the SOS response, ROS generation, and down-regulation of global regulatory genes associated with HGT (korA, korB, and trb) **(65)**. In addition to conjugative transfer of ARGs, heavy metals such as Hg(II), Cu(II), Zn(II) and Cd(II) have been reported to exert AMR through co-selection **(66)**. BacMet is an accurately curated database of bacterial genes that show resistance to metals and antibacterial biocides. It is interesting to note that, according to BacMet, metals and metalloids such as Cu and arsenic have a large number of genes associated with resistance **(67)**.

Vanadium is used as a steel additive and is also found in jet and ship fuels. High concentrations of vanadium have been reported in coastal sediments, raising concerns about its influence on the marine environment. An investigation by Suzuki *et al* **(68)** demonstrated that vanadium can promote the horizontal transfer of ARGs from Photobacterium to *E. coli*.

Liu *et al* **(69)** demonstrated that humic acid-like substances dissolved in biochar affect the transfer efficiency of ARGs between bacteria, with lower levels of humic acid-like substances in biochar significantly affecting conjugative transfer in bacteria.

Microplastics are a growing environmental concern due to their ubiquitous environmental occurrence, mainly in rivers and oceans. Human activities have been reported to be responsible for the accumulation of riverine microplastics. Microplastics serve as an ideal niche for microorganisms to live, colonized, and grow as biofilms **(70)**. A recent study investigated the role of microplastics (polyethylene, polypropylene, polystyrene, polyethylene-fiber, and poly-ethylene-fiber-polyethylene) as vectors for disseminating ARGs in riverine environments. The findings suggest a potential threat of ARG exposure for humans in urban areas that rely on river water **(71)**.

The improper use and disposal of clinical antibiotics has drawn significant attention in environmental research. Studies indicate that the presence of antibiotics in water and soil has a direct impact on the development of AMR in bacteria, which eventually affects the ecosystem **(72)**. A recent investigation indicates that cadmium stress enhanced the degradation of meropenem, a β-lactam antibiotic, by a meropenem resistant strain *P. putida* R51, indicating the potential use of this strain in bioremediation under cadmium stress **(73)**.

In agriculture, by controlling weed populations, herbicides ensure maximum crop productivity and plant growth. However, the overuse and widespread application of herbicides have raised environmental concerns about their impact on development of AMR **(74)**. A recent study shows that commonly used herbicides, glyphosate, glufosinate, and dicamba trigger the dissemination of ARGs via conjugative transfer of MDR plasmids, facilitated by alterations to the cell membrane permeability and proton motive force **(75)**. The herbicide atrazine was found to reduce the susceptibility profile to aztreonam in isolates of *P. aeruginosa* **(76)**.

In addition to herbicides, pesticides are also associated with the development of AMR. A study by Pasha *et al* **(77)** showed that pesticide imidacloprid can significantly influence resistance to antibiotics like carbapenems, aminoglycosides, and cephalosporins. In the environments where antibiotics and pesticides present together, there is a higher chance of development of streptomycin resistance in pathogenic *E. coli* strains, posing a serious threat to public health **(78)**. Notably, commonly used disinfectants like hexadecylpyridinium chloride, sodium hypochlorite, and peracetic acid have also been identified as a risk factor for inducing AMR **(79)**. Figure 2 illustrates a summary of environmental chemical toxins driving AMR.

These toxins include heavy metals, such as zinc and silver, various forms of metal nanoparticles, pesticides, disinfectants, as well as several pharmaceuticals like antibiotics, antifungal agents, and chemotherapeutics.



Figure 2. The environmental chemical toxins that contribute to antimicrobial resistance (AMR). These toxins include heavy metals, such as zinc and silver, various forms of metal nanoparticles, pesticides, disinfectants, as well as several pharmaceuticals like antibiotics, antifungal agents, and chemotherapeutics **(Prepared by Authors, 2025)**.

5. Role of Environment in Spread of AMR to and Among Pathogens

Antibiotic resistance may also occur as a response to environmental exposure. Novel types of antibiotic resistance would originate through mutagenic alterations to the key genes that may encode critical proteins such as the antibiotic targets or transport proteins. This will render the antibiotic ineffective against resulting new strain. Such a *de novo* mutation, if compatible with survival, will provide an advantage for the strain, allowing it to survive and propagate in the presence of the antibiotic **(10, 56)**.

The mobilization of ARGs is thought to have evolved from immobile chromosomal genes that acquired mobile elements such as insertion sequences or integrons and subsequently transferred onto plasmids allowing the mobilization of the genes and passage to other bacteria within the same species or different species through HGT **(10)**. The presence of mobile elements on some of the ARGs found in the arctic permafrost isolates supports this concept **(56)**.

HGT has been identified as the major mechanism for the spread ARGs among bacteria in the environment, contributing to the spread of drug-resistant pathogens across species boundaries. It may occur through mechanisms such as transformation, transduction, and conjugation (Figure 3).



Figure 3. Evolution and Transmission of antibiotic resistance genes (ARGs) in bacteria. An antibiotic resistance gene (ARG) (red bar) arises as a mutation in response to exposures (highlighted in blue) (which may even be self-produced). Mobile elements (green bars) are acquired during evolution allowing the ARG to transfer to a plasmid or a phage. After mobilization, the ARG is more easily spread to other bacteria (green arrows) through several mechanisms (highlighted in green) **(Prepared by Authors, 2025)**.

5.1 Evolutionary Pressure and Fitness Cost

Although bacteria possess inherent mechanisms for HGT of ARGs, permanent establishment of these mobile elements, leading to development of resistant strains would require the establishment of a balance between fitness cost for their maintenance as well as a positive selection pressure. The fitness cost may be high where their expression may interfere with critical cellular functions or until the gene has evolved sufficiently to optimal expression levels **(80)**. A positive selection pressure from the environment, therefore, would be required to maintain these genes until the fitness cost has been fine-tuned **(80)**. Positive selection pressure has been found to be induced when exposed not only to antibiotics in the environment but also to heavy metals **(81, 82)** and other biocides **(83)**, where co-selection of resistance has been often observed.

Exposure to inhibitory levels of chemicals may simultaneously select for the antibiotic resistance along with resistance for the chemical in a process termed co-selection. Co-selection can occur through three mechanisms: namely (i) co-resistance (multiple resistance genes are genetically linked and transferred together), (ii) cross-resistance (where one mechanism provides resistance to more than one agent eg. multi drug efflux pumps), and (iii) co-regulation (linked regulation of gene expression leading to a coordinated response, for example, exposure to a single agent leads to expression of multiple efflux pumps) **(84)**.

In recent years, environmental contamination with clinically used antibiotics has become a significant

concern. These antibiotics enter the environment through improper disposal of used /unused antibiotics and via human / animal excretions. Antibiotic contamination may exceed concentrations required for the resistance in certain places **(10)**, imparting a huge positive selection pressure, which will promote HGT of ARGs across species boundaries.

6. Strategies for the Development of New Antimicrobials

The current global urgency necessitates the development of novel antibiotics that need to stay ahead of the rate of resistance appearance. Many of the antibiotic classes in clinical use are targeted against cell wall synthesis and protein synthesis and are of bacterial origin. Therefore, it is important to identify novel antibiotics with new cellular targets.

The environmental microbiome contains an immense and diverse gene pool of yet undiscovered bioactive secondary metabolite encoding genes. Modern approaches for antibiotic discovery, such as target-based discovery platforms and genome-mining approaches, over the traditional activity-based approaches, have the potential to efficiently yield fruitful results **(85)**.

Recently, antimicrobial peptides have emerged as promising alternative to conventional antibiotics. A lasso peptide antibiotic, lariocidin from *Paenibacillus* sp M2 that inhibits bacterial protein synthesis by binding to the ribosome was reported **(86)**. A novel class of antibiotics that are promising inhibitors of Gram-negative bacteria was reported by Pahil *et al* **(87)**. The macrocyclic peptide antibiotic traps the lipopolysaccharide within the transport machine of *Acinetobacter* and thereby stalls the export of lipopolysaccharides required for the outer membrane synthesis.

Although penicillin, the first natural antibiotic discovered, originated from a fungus, a majority of the antibiotics in clinical use have since come from bacteria and mostly Streptomyces (Table 1). One must ask, however, if this is reflection of the potency of antimicrobial production or if it is skewed by the approaches taken by scientific investigations? The diversity of fungi and their resilience in harsh environments promises immense reservoir of novel secondary metabolites having potent antimicrobial properties, and possibly novel targets.

Fungal genes encoding secondary metabolites have been found to be clustered together in the genome (Biosynthetic Gene Clusters; BGCs), a majority that remain silent, particularly under laboratory conditions. Activity-based approaches would require the identification of mechanisms to induce these pathways. Self-survival of antibiotic secretors necessitates that resistance genes co-evolve alongside antibiotic biosynthetic pathways. Interestingly, these resistance genes have been often found co-localized within the BGCs **(58)**. Several databases and screening tools are currently available (eg. DeepBGC fungal, FungiSMASH, TOUCAN) for mining fungal BGCs. The 'fungal bioactive compound resistant target seeker' (FunARTS) reported recently is an open-source mining tool that allows target-driven genome-mining **(88)**.

7. Conclusion

The spread of antimicrobial resistance to existing last line antibiotics in recent years looms as an impending crisis in upcoming years. In addition to microbial stewardship to control the spread of resistant microbes, the need to discover or develop novel antimicrobial classes for which resistance mechanisms have not spread to clinically relevant strains, has become urgent. The complex chemical structures of natural products, which are not necessarily reproducible through chemical synthesis in the current context, lend value to the search for natural antibiotics. It should not be considered that the natural antibiotic reservoir has been exhausted. The recent discovery of lasso peptides by Jangra *et al* (86) is an example. Natural products discovery should target extremophiles and rare microorganisms from non-conventional environments. Un-culturable bacteria may offer yet undiscovered material. Natural product discovery efforts need to be armed with modern tools such as genomics, transcriptomics, proteomics, and AI based design strategies for protein engineering and synthetic biology. Sustainable investments are needed to stimulate the establishment of novel drug discovery platforms, as recommended by the UK Government commissioned O'Neill report and WHO efforts.

8. Declarations

8.1 Acknowledgment

The authors thank the support given by the Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo 08, Sri Lanka.

8.2 Ethical Considerations

Not applicable.

8.3 Authors' Contributions

SJ: conceptualization, writing and reviewing; MKE: writing, reviewing and editing; CU: writing and editing; Reading the final version of manuscript: all authors.

8.4 Conflict of Interests

There are no conflicts of interest to declare.

8.5 Financial Support and Sponsorship

No financial support or sponsorship was obtained for this research.

8.6 Using Artificial Intelligence Tools (AI Tools)

AI tools were not utilized in writing this review.

References

1. O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;2014.
2. World Health Organization (WHO). Global action plan on antimicrobial resistance. Microbe Magazine. 2015;10(9):354-5.
3. Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 2024;22(10):598-616. [PMID] [DOI:10.1038/s41579-024-01054-w]
4. Chin KL, Anibarro L, Chang ZY, Palasuberniam P, Mustapha ZA, Sarmiento ME, et al. Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities. Curr Res Microb Sci. 2024;7:100295. [PMCID] [DOI:10.1016/j.crmicr.2024.100295] [PMID]
5. Sun J, Chen C, Cui CY, Zhang Y, Liu X, Cui ZH, et al. Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat Microbiol. 2019;4(9):1457-64. [PMID] [DOI:10.1038/s41564-019-0496-4] [PMCID]
6. Caldera JR, Shaw B, Uslan DZ, Yang S. Cluster of extensively drug-resistant Shigella sonnei carrying bla(CTX-M-15) in Los Angeles, California, 2023 to 2024. Am J Infect Control. 2025;53(4):524-6. [DOI:10.1016/j.ajic.2024.12.005] [PMID]
7. Liu H, Moran RA, Doughty EL, Hua X, Snaith AE, Zhang L, et al. Longitudinal genomics reveals carbapenem-resistant Acinetobacter baumannii population changes with emergence of highly resistant ST164 clone. Nat Commun. 2024;15(1):9483. [PMID] [PMCID] [DOI:10.1038/s41467-024-53817-x]
8. Nyamngee A, Ikpe RT, Sulaiman MK. Prevalence of molecular markers associated with Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in three malaria endemic local areas of Benue State, Nigeria. Pan Afr Med J. 2025;50:73. [DOI:10.11604/pamj.2025.50.73.45826][PMID] [PMCID]
9. Aw DZH, Zhang DX, Vignuzzi M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. NPJ Antimicrob Resist. 2025;3(1):54. [DOI:10.1038/s44259-025-00125-z] [PMID] [PMCID]
10. Larsson DJ, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20(5): 257-69. [DOI:10.1038/s41579-021-00649-x] [PMID] [PMCID]
11. Ariyawansa S, Gunawardana KN, Hapudeniya MM, Manelgamage NJ, Karunarathne CR, Madalagama RP, et al. One Health Surveillance of Antimicrobial Use and Resistance: Challenges and Successes of Implementing Surveillance Programs in Sri Lanka. Antibiotics. 2023;12(3): 446. [DOI:10.3390/antibiotics12030446] [PMID] [PMCID]
12. Sihombing B, Bhatia R, Srivastava R, Aditama TY, Laxminarayan R, Rijal S. Response to antimicrobial resistance in South-East Asia Region. Lancet Reg Health Southeast Asia. 2023;18. [DOI:10.1016/j.lansea.2023.100306] [PMID] [PMCID]
13. Taylor P, Reeder R. Antibiotic use on crops in low and middle-income countries based on recommendations made by agricultural advisors. CABI Agric Biosci. 2020;1(1):1. [DOI:10.1186/s43170-020-00001-y]
14. Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. Br J Exp Pathol. 1929;10(3):226-36.
15. Samreen, Ahmad I, Malak HA, Abulreesh HH. Environmental antimicrobial resistance and its drivers: a potential threat to public health. J Glob Antimicrob Resist. 2021;27:101-11. [DOI:10.1016/j.jgar.2021.08.001] [PMID]
16. Kashuba E, Dmitriev AA, Kamal SM, Melefors O, Griva G, Römling U, et al. Ancient permafrost

staphylococci carry antibiotic resistance genes. Microb Ecol Health Dis. 2017;28(1):1345574. [DOI:10.1080/16512235.2017.1345574][PMID] [PMCID]

17. Nawaz S, Rafiq M, Pepper IL, Betancourt WQ, Shah AA, Hasan F. Prevalence and abundance of antibiotic-resistant genes in culturable bacteria inhabiting a non-polar passu glacier, karakorum mountains range, Pakistan. World J Microbiol Biotechnol. 2023;39(4):94. [DOI:10.1007/s11274-023-03532-4] [PMID]
18. Núñez-Montero K, Barrientos L. Advances in Antarctic Research for Antimicrobial Discovery: A Comprehensive Narrative Review of Bacteria from Antarctic Environments as Potential Sources of Novel Antibiotic Compounds Against Human Pathogens and Microorganisms of Industrial Importance. Antibiotics. 2018;7(4): 90. [DOI:10.3390/antibiotics7040090] [PMID] [PMCID]
19. Zhuang M, Achmon Y, Cao Y, Liang X, Chen L, Wang H, et al. Distribution of antibiotic resistance genes in the environment. Environ Pollut. 2021;285:117402. [DOI:10.1016/j.envpol.2021.117402] [PMID]
20. Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol. 2007;5(3):175-86. [DOI:10.1038/nrmicro1614] [PMID]
21. Waksman SA, Albert S, inventors; Rutgers Research, Educational Foundation, assignee. Streptomycin and process of preparation. United States patent US 2,449,866. 1948.
22. Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. MedChemComm. 2016;7(1):11-27. [DOI:10.1039/C5MD00344J] [PMID] [PMCID]
23. Ehrlich J, Bartz QR, Smith RM, Joslyn DA, Burkholder PR. Chloromycetin, a New Antibiotic From a Soil Actinomycete. Science. 1947; 106(2757):417. [DOI:10.1126/science.106.2757.417] [PMID]
24. Ehrlich J, Smith RM, Penner MA, inventors; Parke Davis and Co LLC assignee. Process for the manufacture of chloramphenicol patent US2483892A. 1948. [https://patents.google.com/patent/US2483892A/en]
25. Duggar BM, inventor; American Cyanamid Company, assignee. Aureomycin and preparation of same patent US2482055A. 1948. [https://patents.google.com/patent/US2482055A/en]
26. Polikanov YS, Aleksashin NA, Beckert B, Wilson DN. The Mechanisms of Action of Ribosome-Targeting Peptide Antibiotics. Front Mol Biosci. 2018;5:48. [DOI:10.3389/fmolb.2018.00048] [PMID] [PMCID]
27. P'an SY, Halley TV, Reilly JC, Pekich AM. Viomycin: Acute and Chronic Toxicity in Experimental Animals. Amer Rev Tuberc. 1951; 63(1):44-8.
28. Bunch RL, Mcguire JM, inventors; Eli Lilly and Company, assignee. Erythromycin, its salts, and method of preparation patent US2653899A. 1952. [https://patents.google.com/patent/US2653899A/en]
29. Sutcliffe JA, Leclercq R. Mechanisms of resistance to macrolides, lincosamides, and ketolides. In: Schönfeld W, Kirst HA, editors. Macrolide Antibiotics. Basel: Birkhäuser Basel; 2002. pp. 281-317. [DOI:10.1007/978-3-0348-8105-0_17]
30. Charney J, Fisher WP, Curran C, Machlowitz RA, Tytell AA. Streptogramin, a new antibiotic. Antibiot Chemother (Northfield). 1953;3(12): 1283-6.
31. McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot Annu. 1955;3:606-11.
32. Binda E, Cappelletti P, Marinelli F, Marcone GL. Specificity of Induction of Glycopeptide Antibiotic Resistance in the Producing Actinomycetes. Antibiotics. 2018;7(2). [PMID] [DOI:10.3390/antibiotics7020036] [PMCID]
33. Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. Structure and Reactions of Cycloserine. J Am Chem Soc. 1955; 77(8):2345-6. [DOI:10.1021/ja01613a106]
34. Evangelopoulos D, Prosser GA, Rodgers A, Dagg BM, Khatri B, Ho MM, et al. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Nat Commun. 2019;10(1): 4177. [DOI:10.1038/s41467-019-12074-z] [PMID] [PMCID]
35. Argoudelis AD, Fox JA, Mason DJ. Studies on the Biosynthesis of Lincomycin. II. Antibiotic U-11,973, N-Demethyl Lincomycin*. Biochemistry. 1965;4(4):710-3. [DOI:10.1021/bi00880a016] [PMID]

36. Sensi P, Margalith P, Timbal MT. Rifomycin, a new antibiotic; preliminary report. Farmaco Sci. 1959;14(2):146-7.

37. Floss HG, Yu TW. Rifamycin Mode of Action, Resistance, and Biosynthesis. Chem Rev. 2005; 105(2):621-32. [DOI:10.1021/cr030112j][PMID]

38. Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med. 2017;7(2):a025262. [PMID] [PMCID] [DOI:10.1101/cshperspect.a025262]

39. Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F, et al. Mechanisms of Action of Carbapenem Resistance. Antibiotics. 2022;11(3):421. [PMID] [PMCID] [DOI:10.3390/antibiotics11030421]

40. Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 2018;73(1):1-11. [DOI:10.1093/jac/dkx349] [PMID]

41. Drugbank. Mupirocin: Drugbank. Available from: [https://go.drugbank.com/drugs/DB00410]

42. Sykes RB, Bonner DP. Aztreonam: The first monobactam. Am J Med. 1985;78(2):2-10. [DOI:10.1016/0002-9343(85)90196-2] [PMID]

43. Liou JW, Hung YJ, Yang CH, Chen YC. The Antimicrobial Activity of Gramicidin A Is Associated with Hydroxyl Radical Formation. PLoS One. 2015;10(1):e0117065. [PMCID] [DOI:10.1371/journal.pone.0117065] [PMID]

44. Radeck J, Gebhard S, Orchard PS, Kirchner M, Bauer S, Mascher T, Fritz G. Anatomy of the bacitracin resistance network in Bacillus subtilis. Mol Microbiol. 2016;100(4):607-20. [DOI:10.1111/mmi.13336] [PMID]

45. Li Z, Cao Y, Yi L, Liu JH, Yang Q. Emergent Polymyxin Resistance: End of an Era?. Open Forum Infect Dis. 2019;6(10):ofz368. [DOI:10.1093/ofid/ofz368] [PMID] [PMCID]

46. King DT, Sobhanifar S, Strynadka NCJ. The Mechanisms of Resistance to β-Lactam Antibiotics. In: Gotte M, Berghuis A, Matlashewski G, Wainberg M, Sheppard D, editors. Handbook of Antimicrobial Resistance. New York, NY: Springer New York; 2014. pp. 1-22.

47. Kavanagh F, Hervey A, Robbins WJ. Antibiotic Substances From Basidiomycetes. Proc Natl Acad Sci USA. 1951;37(9):570-4. [DOI:10.1073/pnas.37.9.570] [PMID] [PMCID]

48. Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L. Fusidic Acid: a New Antibiotic. Nature. 1962;193(4819):987. [DOI:10.1038/193987a0] [PMID]

49. Gram C. The differential staining of Schizomycetes in tissue sections and in dried preparations. Fortschritte der Medizin. 1884;2: 185-9.

50. Feofilova EP. The fungal cell wall: Modern concepts of its composition and biological function. Microbiology. 2010;79(6):711-20. [DOI:10.1134/S0026261710060019]

51. Uruén C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics. 2020;10(1):3. [DOI:10.3390/antibiotics10010003] [PMID] [PMCID]

52. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta - Proteins Proteom. 2009;1794(5):808-16. [DOI:10.1016/j.bbapap.2008.11.005][PMID] [PMCID]

53. Zhang L, Tian X, Sun L, Mi K, Wang R, Gong F, et al. Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance. Pharmaceutics. 2024; 16(2):170. [PMID] [PMCID] [DOI:10.3390/pharmaceutics16020170]

54. Long Y, Wang B, Xie T, Luo R, Tang J, Deng J, et al. Overexpression of efflux pump genes is one of the mechanisms causing drug resistance in Mycobacterium tuberculosis. Microbiol Spectr. 2023;12(1):e02510-23. [PMID] [PMCID] [DOI:10.1128/spectrum.02510-23]

55. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019; 37(1):177-92. [PMID] [DOI:10.1016/j.biotechadv.2018.11.013]

56. Kim H, Kim M, Kim S, Lee YM, Shin SC. Characterization of antimicrobial resistance genes and virulence factor genes in an Arctic permafrost region revealed by metagenomics. Environ Pollut. 2022;294:118634. [DOI:10.1016/j.envpol.2021.118634] [PMID]

57. Mootapally C, Nathani NM, Poriya P, Beleem I, Dabhi JC, Gadhvi IR, et al. Antibiotic Resistome Biomarkers associated to the Pelagic Sediments of the Gulfs of Kathiawar Peninsula and Arabian Sea. Sci Rep. 2019;9:17281. [PMID] [PMCID] [DOI:10.1038/s41598-019-53832-9]

58. Nathani NM, Mootapally C, Dave BP. Antibiotic resistance genes allied to the pelagic sediment microbiome in the Gulf of Khambhat and Arabian Sea. Sci Total Environ. 2019;653:446-54. [DOI:10.1016/j.scitotenv.2018.10.409] [PMID]

59. Lu J, Wang Y, Jin M, Yuan Z, Bond P, Guo J. Both silver ions and silver nanoparticles facilitate the horizontal transfer of plasmid-mediated antibiotic resistance genes. Water Res. 2020; 169:115229. [DOI:10.1016/j.watres.2019.115229] [PMID]

60. Dutt Y, Pandey RP, Dutt M, Gupta A, Vibhuti A, Raj VS, et al. Silver Nanoparticles Phytofabricated through Azadirachta indica: Anticancer, Apoptotic, and Wound-Healing Properties. Antibiotics. 2023;12(1):121. [PMID] [DOI:10.3390/antibiotics12010121] [PMCID]

61. Whiteley CM, Valle MD, Jones KC, Sweetman AJ. Challenges in assessing release, exposure and fate of silver nanoparticles within the UK environment. Environ Sci: Process Impacts. 2013;15(11):2050-8. [DOI:10.1039/c3em00226h] [PMID]

62. Temizel-Sekeryan S, Hicks AL. Global environmental impacts of silver nanoparticle production methods supported by life cycle assessment. Resour Conserv Recycl. 2020;156. [DOI:10.1016/j.resconrec.2019.104676]

63. Jafari S, Mahyad B, Hashemzadeh H, Janfaza S, Gholikhani T, Tayebi L. Biomedical Applications of TiO2 Nanostructures: Recent Advances. Int J Nanomed. 2020;15:3447-70. [DOI:10.2147/IJN.S249441] [PMID] [PMCID]

64. Qiu Z, Shen Z, Qian D, Jin M, Yang D, Wang J, et al. Effects of nano-TiO2 on antibiotic resistance transfer mediated by RP4 plasmid. Nanotoxicology. 2015;9(7):895-904. [DOI:10.3109/17435390.2014.991429] [PMID]

65. Zhang Y, Gu AZ, Cen T, Li X, He M, Li D, et al. Sub-inhibitory concentrations of heavy metals facilitate the horizontal transfer of plasmid-mediated antibiotic resistance genes in water environment. Environ Pollut. 2018;237:74-82. [DOI:10.1016/j.envpol.2018.01.032] [PMID]

66. Singh CK, Sodhi KK, Shree P, Nitin V. Heavy Metals as Catalysts in the Evolution of Antimicrobial Resistance and the Mechanisms Underpinning Co-selection. Curr Microbiol. 2024;81(6):148. [PMID] [DOI:10.1007/s00284-024-03648-2]

67. Pal C, Bengtsson-Palme J, Rensing C, Kristiansson E, Larsson DGJ. BacMet: antibacterial biocide and metal resistance genes database. Nucleic Acids Res. 2014; 42(D1):D737-D43. [DOI:10.1093/nar/gkt1252] [PMID] [PMCID]

68. Suzuki S, Kimura M, Agusa T, Rahman HM. Vanadium accelerates horizontal transfer of tet(M) gene from marine Photobacterium to Escherichia coli. FEMS Microbiol Lett. 2012; 336(1):52-6. [PMID] [DOI:10.1111/j.1574-6968.2012.02653.x]

69. Liu X, Wang D, Tang J, Liu F, Wang L. Effect of dissolved biochar on the transfer of antibiotic resistance genes between bacteria. Environ Pollut. 2021;288:117718. [DOI:10.1016/j.envpol.2021.117718] [PMID]

70. Sooriyakumar P, Bolan N, Kumar M, Singh L, Yu Y, Li Y, et al. Biofilm formation and its implications on the properties and fate of microplastics in aquatic environments: A review. J Hazard Mater Adv. 2022;6:100077. [DOI:10.1016/j.hazadv.2022.100077]

71. Li R, Zhu L, Yang K, Li H, Zhu YG, Cui L. Impact of Urbanization on Antibiotic Resistome in Different Microplastics: Evidence from a Large-Scale Whole River Analysis. Environ Sci Technol. 2021;55(13):8760-70. [DOI:10.1021/acs.est.1c01395] [PMID]

72. Kaviani Rad A, Balasundram SK, Azizi S, Afsharyzad Y, Zarei M, Etesami H, et al. An overview of antibiotic resistance and abiotic stresses affecting antimicrobial resistance in agricultural soils. Int J Environ Res Public Health. 2022;19(8):4666. [DOI:10.3390/ijerph19084666] [PMID] [PMCID]

73. Zhong C, Zhou Y, Fu J, Qi X, Wang Z, Li J, et al. Cadmium stress efficiently enhanced meropenem degradation by the meropenem- and cadmium-resistant strain Pseudomonas putida R51. J Hazard Mater. 2022;429:128354. [DOI:10.1016/j.jhazmat.2022.128354] [PMID]

74. Miller SA, Ferreira JP, LeJeune JT. Antimicrobial Use and Resistance in Plant Agriculture: A One Health Perspective. Agriculture. 2022;12(2): 289. [DOI:10.3390/agriculture12020289]

75. Li X, Wen C, Liu C, Lu S, Xu Z, Yang Q, et al. Herbicide promotes the conjugative transfer of multi-resistance genes by facilitating cellular contact and plasmid transfer. J Environ Sci. 2022;115:363-73. [DOI:10.1016/j.jes.2021.08.006] [PMID]

76. Braz VS, Moretto JAS, Fernandes AFT, Stehling EG. Change in the antimicrobial resistance profile of Pseudomonas aeruginosa from soil

after exposure to herbicides. J Environ Sci Health B. 2019;54(4):290-3. [PMID] [DOI:10.1080/03601234.2018.1561056]

77. Pasha SAR, Namitha BN, Ismail W, Gowri R, Natarajan A. Experiment to Demonstrate Pesticide-Induced Antimicrobial Resistance (AMR): An Emerging Health Threat. Cureus. 2024;16(2):e54243. [DOI:10.7759/cureus.54243] [PMID] [PMCID]

78. Xing Y, Herrera D, Zhang S, Kang X, Men Y. Site-specific target-modification mutations exclusively induced by the coexposure to low levels of pesticides and streptomycin caused strong streptomycin resistance in clinically relevant Escherichia coli. J Hazard Mater Adv. 2022;7:100141. [DOI:10.1016/j.hazadv.2022.100141]

79. Cadena M, Kelman T, Marco ML, Pitesky M. Understanding Antimicrobial Resistance (AMR) Profiles of Salmonella Biofilm and Planktonic Bacteria Challenged with Disinfectants Commonly Used During Poultry Processing. Foods. 2019;8(7):275. [DOI:10.3390/foods8070275] [PMID] [PMCID]

80. Bengtsson-Palme J, Kristiansson E, Larsson DGJ. Environmental factors influencing the development and spread of antibiotic resistance. FEMS Microbiol Rev. 2018;42(1): fux053. [DOI:10.1093/femsre/fux053] [PMID] [PMCID]

81. Vats P, Kaur UJ, Rishi P. Heavy metal-induced selection and proliferation of antibiotic resistance: A review. J Appl Microbiol. 2022; 132(6):4058-76. [DOI:10.1111/jam.15492] [PMID]

82. Zhang S, Wang Y, Song H, Lu J, Yuan Z, Guo J. Copper nanoparticles and copper ions promote horizontal transfer of plasmid-mediated multi-antibiotic resistance genes across bacterial genera. Environ Int. 2019;129:478-87. [DOI:10.1016/j.envint.2019.05.054] [PMID]

83. Seier-Petersen MA, Jasni A, Aarestrup FM, Vigre H, Mullany P, Roberts AP, Agersø Y. Effect of subinhibitory concentrations of four commonly used biocides on the conjugative transfer of Tn916 in Bacillus subtilis. J Antimicrob Chemother. 2014;69(2):343-8. [DOI:10.1093/jac/dkt370] [PMID] [PMCID]

84. Murray LM, Hayes A, Snape J, Kasprzyk-Hordern B, Gaze WH, Murray AK. Co-selection for antibiotic resistance by environmental contaminants. NPJ Antimicrob Resist. 2024; 2(1):1-13. [DOI:10.1038/s44259-024-00026-7] [PMID] [PMCID]

85. Zerikly M, Challis GL. Strategies for the Discovery of New Natural Products by Genome Mining. ChemBioChem. 2009;10(4):625-33. [DOI:10.1002/cbic.200800389] [PMID]

86. Jangra M, Travin DY, Aleksandrova EV, Kaur M, Darwish L, Koteva K, et al. A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome. Nature. 2025;640(8060):1022-30. [DOI:10.1038/s41586-025-08723-7] [PMID] [PMCID]

87. Pahil KS, Gilman MSA, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature. 2024;625(7995):572-7. [DOI:10.1038/s41586-023-06799-7] [PMID] [PMCID]

88. Yılmaz TM, Mungan MD, Berasategui A, Ziemert N. FunARTS, the Fungal bioActive compound Resistant Target Seeker, an exploration engine for target-directed genome mining in fungi. Nucleic Acids Res. 2023;51(W1):W191-W7. [DOI:10.1093/nar/gkad386] [PMID] [PMCID]